Interrogating open issues in cancer precision medicine with patient-derived xenografts by Byrne, Annette T. et al.
 
 
 
 
Byrne, A. T. et al. (2017) Interrogating open issues in cancer precision 
medicine with patient-derived xenografts. Nature Reviews Cancer, 17, pp. 
254-268. (doi:10.1038/nrc.2016.140) 
 
This is the author’s final accepted version. 
 
There may be differences between this version and the published version. 
You are advised to consult the publisher’s version if you wish to cite from 
it. 
 
 
 
 
http://eprints.gla.ac.uk/136126/ 
     
 
 
 
 
 
 
Deposited on: 09 March 2017 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
  1 
Opinion 
 
Interrogating open issues in cancer precision medicine with patient-
derived xenografts 
 
Annette T. Byrne, Denis G. Alférez, Frédéric Amant, Daniela Annibali, 
Joaquín Arribas, Andrew V. Biankin, Alejandra Bruna, Eva Budinská, Carlos 
Caldas, David K. Chang, Robert B. Clarke, Hans Clevers, George Coukos, 
Virginie Dangles-Marie, S. Gail Eckhardt, Eva Gonzalez-Suarez, Els 
Hermans, Manuel Hidalgo, Monika A. Jarzabek, Steven de Jong, Jos Jonkers, 
Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta 
Marangoni, Jean-Christophe Marine, Enzo Medico, Jens Henrik Norum, 
Héctor G. Palmer, Daniel S. Peeper, Pier Giuseppe Pelicci, Alejandro Piris-
Gimenez, Sergio Roman-Roman, Oscar M. Rueda, Joan Seoane, Violeta 
Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, 
Andrea Bertotti and Livio Trusolino 
 
Annette T. Byrne and Monika A. Jarzabek are members of the EurOPDX 
Consortium and are at the Royal College of Surgeons in Ireland, Dublin 2, 
Ireland. 
Denis G. Alférez and Robert B. Clarke are members of the EurOPDX 
Consortium and are at the Breast Cancer Now Research Unit, Division of 
Molecular and Clinical Cancer Sciences, Manchester Cancer Research 
Centre, University of Manchester, Manchester M20 4QL, UK. 
  2 
Frédéric Amant, Daniela Annibali and Els Hermans are members of the 
EurOPDX Consortium and are at the Katholieke Universiteit Leuven, 3000 
Leuven, Belgium. Frédéric Amant is also at The Netherlands Cancer 
Institute, Plesmanlaan 121, 1066CX Amsterdam, The Netherlands. 
Joaquín Arribas, Joan Seoane and Laura Soucek are members of the 
EurOPDX Consortium and are at the Vall d’Hebron Institute of Oncology, 
08035 Barcelona, the Universitat Autònoma de Barcelona, 08193 
Bellaterra, and the Institució Catalana de Recerca i Estudis Avançats 
(ICREA), 08010 Barcelona, Spain. Joaquín Arribas and Joan Seoane are 
also at CIBERONC, 08035 Barcelona, Spain. 
Andrew V. Biankin and David K. Chang are members of the EurOPDX 
Consortium and are at the Wolfson Wohl Cancer Research Centre, Institute of 
Cancer Sciences, University of Glasgow, Glasgow G61 1QH, UK. 
Alejandra Bruna, Carlos Caldas and Oscar M. Rueda are members of the 
EurOPDX Consortium and are at Cancer Research UK Cambridge Institute, 
Cambridge Cancer Centre, University of Cambridge, Cambridge CB2 0RE, 
UK. 
Eva Budinská is a member of the EurOPDX Consortium and is at the 
Institute of Biostatistics and Analyses, Faculty of Medicine, and Research 
Centre for Toxic Compounds in the Environment, Faculty of Science, 
Masarykova Univerzita, 625 00 Brno, Czech Republic. 
Hans Clevers is at the Hubrecht Institute, University Medical Centre Utrecht, 
and Princess Maxima Center for Pediatric Oncology, 3584CT Utrecht, The 
Netherlands. 
  3 
George Coukos and Dominique Vanhecke are members of the EurOPDX 
Consortium and are at Lausanne Branch, Ludwig Institute for Cancer 
Research at the University of Lausanne, 1066 Lausanne, Switzerland. 
Virginie Dangles-Marie is a member of the EurOPDX Consortium and is at 
the Institut Curie, PSL Research University, Translational Research 
Department, 75005 Paris, and Université Paris Descartes, Sorbonne Paris 
Cité, Faculté de Pharmacie de Paris, 75006 Paris, France. 
S. Gail Eckhardt is at the University of Colorado Cancer Center, Aurora, 
Colorado 80045, USA. 
Eva Gonzalez-Suarez is a member of the EurOPDX Consortium and is at 
the Cancer Epigenetics and Biology Program, Bellvitge Biomedical 
Research Institute IDIBELL, 08908 L’Hospitalet de Llobregat, Barcelona, 
Spain. 
Manuel Hidalgo is a member of the EurOPDX Consortium and is at Beth 
Israel Deaconess Medical Center, Boston, Harvard Medical School, Boston, 
Massachusetts 02215, USA. 
Steven de Jong is a member of the EurOPDX Consortium and is at the 
University Medical Centre Groningen, University of Groningen, 9713GZ 
Groningen, The Netherlands. 
Jos Jonkers, Kristel Kemper and Daniel S. Peeper are members of the 
EurOPDX Consortium and are at The Netherlands Cancer Institute, 
Plesmanlaan 121, 1066CX Amsterdam, The Netherlands. 
  4 
Luisa Lanfrancone and Pier Giuseppe Pelicci are members of the EurOPDX 
Consortium and are at the Department of Experimental Oncology, European 
Institute of Oncology, 20139 Milan, Italy. 
Gunhild Mari Mælandsmo and Jens Henrik Norum are members of the 
EurOPDX Consortium and are at Oslo University Hospital, Institute for 
Cancer Research, 0424 Oslo, Norway. 
Elisabetta Marangoni and Sergio Roman-Roman are members of the 
EurOPDX Consortium and are at Institut Curie, PSL Research University, 
Translational Research Department, 75005 Paris, France. 
Jean-Christophe Marine is a member of the EurOPDX Consortium and is at 
the Laboratory for Molecular Cancer Biology, Department of Oncology, 
Katholieke Universiteit Leuven, and the Center for Cancer Biology, VIB, 3000 
Leuven, Belgium. 
Enzo Medico, Andrea Bertotti and Livio Trusolino are members of the 
EurOPDX Consortium and are at the Candiolo Cancer Institute IRCCS and 
Department of Oncology, University of Torino, 10060 Candiolo, Torino, 
Italy. 
Héctor G. Palmer, Alejandro Piris-Gimenez and Violeta Serra are members 
of the EurOPDX Consortium and are at the Vall d’Hebron Institute of 
Oncology and CIBERONC, 08035 Barcelona, Spain. 
Alberto Villanueva is a member of the EurOPDX Consortium and is at the 
Program Against Cancer Therapeutic Resistance (ProCURE), Catalan Institute 
of Oncology ICO, Bellvitge Biomedical Research Institute IDIBELL, 08098 
  5 
L’Hospitalet de Llobregat, Barcelona, and Xenopat S.L., Business 
Bioincubator, Bellvitge Health Science Campus, 08907 L’Hospitalet 
de Llobregat, Barcelona, Spain. 
Emilie Vinolo is at Seeding Science SAS, 75020 Paris, France. 
 
Correspondence to A.T.B. and L.T. 
annettebyrne@rcsi.ie; 
livio.trusolino@ircc.it 
 
doi:10.1038/nrc.2016.140 
Published online 20 Jan 2017 
 
Abstract 
Patient-derived xenografts (PDXs) have emerged as an important platform to 
elucidate new treatments and biomarkers in oncology. PDX models are used 
to address clinically relevant questions, including the contribution of tumour 
heterogeneity to therapeutic responsiveness, the patterns of cancer 
evolutionary dynamics during tumour progression and under drug pressure, 
and the mechanisms of resistance to treatment. The ability of PDX models to 
predict clinical outcomes is being improved through mouse humanization 
strategies and implementation of co-clinical trials, within which patients and 
PDXs reciprocally inform therapeutic decisions. This Opinion article discusses 
aspects of PDX modelling that are relevant to these questions and highlights 
the merits of shared PDX resources to advance cancer medicine from the 
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perspective of EurOPDX, an international initiative devoted to PDX-based 
research. 
 
 
 
Response to anticancer therapies varies owing to the substantial molecular 
heterogeneity of human tumours and to poorly defined mechanisms of drug 
efficacy and resistance1. Immortalized cancer cell lines, either cultured in vitro 
or grown as xenografts, cannot interrogate the complexity of human tumours, 
and only provide determinate insights into human disease, as they are limited 
in number and diversity, and have been cultured on plastic over decades2. 
This disconnection in scale and biological accuracy contributes considerably 
to attrition in drug development3-5. 
 
Surgically derived clinical tumour samples that are implanted in mice (known 
as patient-derived xenografts (PDXs)) are expected to better inform 
therapeutic development strategies. As intact tissue - in which the tumour 
architecture and the relative proportion of cancer cells and stromal cells are 
both maintained -  is directly implanted into recipient animals, the alignment 
with human disease is enhanced. More importantly, PDXs retain the 
idiosyncratic characteristics of different tumours from different patients; hence, 
they can effectively recapitulate the intra-tumour and inter-tumour 
heterogeneity that typifies human cancer6-9. 
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Exhaustive information on the key characteristics and the practical 
applications of PDXs can be found in recent reviews10-13. In this Opinion 
article, we discuss basic methodological concepts, as well as challenges and 
opportunities in developing “next-generation” models to improve the reach of 
PDXs as preclinical tools for in vivo studies (TABLE 1). We also elaborate on 
the merits of PDXs for exploring the intrinsic heterogeneity and subclonal 
genetic evolution of individual tumours, and discuss how this may influence 
therapeutic resistance. Finally, we examine the utility of PDXs in navigating 
complex variables in clinical decision-making, such as the discovery of 
predictive and prognostic biomarkers, and the categorization of genotype-drug 
response correlations in high-throughput formats. Being primarily co-authored 
by leading members of the EurOPDX Consortium (see Further information), 
we provide a perspective on the value of PDX models as an important 
resource for the international cancer research community towards the 
realization of a precision medicine paradigm (BOX 1; TABLE 2). 
 
 
Modelling cancer phenotypes 
Interrogating intra-tumour heterogeneity and evolutionary dynamics. 
Cancer is increasingly being recognized as an ecosystem of cells that 
constantly evolves following Darwinian laws. Owing to cancer cell intrinsic 
mutability, an incipient tumour clone gives rise to a progeny of genetically 
heterogeneous subclones, some of which will thrive while others shrink, 
depending on their ability to cope with environmental selection pressures14. 
This is of particular relevance for cancer treatment, as most patients will 
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eventually succumb to the disease owing to the appearance of resistant 
tumour subclones. Despite the considerable clinical impact of tumour 
heterogeneity15, little is known about how it affects response to cancer therapy 
and how it may change during treatment at both the genomic and the 
phenotypic levels16-20. These issues highlight the need for preclinical models 
that capture the heterogeneous nature of human cancers and their on-going 
evolution.  
 
For example, breast cancer is a constellation of at least 10 different genomic 
subtypes, each with distinct drivers and variable intra-tumour 
heterogeneity15,21,22. Recent evidence has suggested that each breast cancer 
comprises multiple tumour cell populations with distinct evolutionary 
trajectories that are likely to be affected by treatment pressure23-25. Genomic 
evolution between primary and recurrent tumours also occurs24-28. Such intra-
tumour and inter-tumour variability affects therapeutic responses, and hence 
needs to be considered in the preclinical and clinical settings. Although some 
engraftment-associated selection has been documented24,29, PDX models of 
breast cancer seemingly preserve most of the genomic clonal architecture of 
the original patient sample and also seem to resemble patient counterparts at 
the transcriptomic, epigenomic and histological levels, as well as in terms of 
shared signalling pathways8,30-32. Notably, the majority of tumour subclones 
that change upon engraftment do not include known breast cancer oncogenic 
drivers29. This suggests that, although engraftment pressure is observed, it is 
evolutionarily neutral, as it does not affect intra-tumour heterogeneity when 
considering the clonal representation of relevant genes. These features 
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probably underpin the successful use of breast cancer PDXs to predict clinical 
drug responses9 and mechanisms of acquired resistance33,34.  
 
As discussed below, an advantage of PDX models is that they can be 
generated with a limited amount of material; for example, using fine-needle 
biopsies (TABLE 1). However, these methods may be confounding when the 
studied tumour type is particularly heterogeneous (such as melanoma). For 
example, within one tumour or metastasis, multiple melanoma subclones can 
exist, each harbouring different genetic and/or epigenetic alterations35-37. 
Simply taking a single biopsy sample can result in a PDX that does not 
represent the heterogeneity of the patient’s tumour35,38. Notably, regional 
genetic variability can be exacerbated by PDX serial propagation, producing 
divergent responses in tumour measurements within a single cohort of treated 
mice32,39. Methods to overcome this limitation include good, standardized pre-
clinical designs (those with adequate statistical power and proper 
randomization), as well as the mixing of heterogeneous tumour masses 
before implantation, such as through the use of single-cell suspension 
injections or rough tumour homogenates24. 
 
The direct derivation of PDXs from circulating tumour cells (CTCs) may 
represent another tool to further interrogate tumour heterogeneity. The 
numbers of cancer cells shed by tumours into the bloodstream may be 
exceedingly low, and the biological and clinical relevance of CTCs in 
sustaining malignant disease has been questioned40. However, as CTCs are 
shed by tumours on a stochastic rather than a deterministic basis41, they are 
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expected to better recapitulate the distribution of different subclonal tumour 
populations (TABLE 1).  
 
Intra-tumoural heterogeneity may also be non-genetic and intrinsic to the 
hierarchical organization of some tumours, in which a small subpopulation of 
cancer stem cells (CSCs) may be responsible for long-term tumourigenicity42-
45. CSCs are thought to be chemoresistant and the main cause of recurrence 
and distant metastasis46-48. Much of the supporting evidence originates from 
PDX models that were directly derived from various clinical samples, including 
CTCs, ascites fluid and pleural effusion cells, and surgical biopsy samples49-
53. PDX models have provided evidence of CSC colonization in metastatic 
sites and have also highlighted the role and importance of the surrounding 
tumour stroma, a niche that is known to influence CSC behaviour by cell-to-
cell contacts and through the secretion of pro-tumorigenic ligands and 
cytokines8,51,54. An ongoing debate exists as to whether CSCs recapitulate the 
full characteristics of stem cells (that is, they are undifferentiated cells with 
limitless replicative potential, which partly self-perpetuate to maintain a 
tumorigenic reservoir and which partly differentiate to give rise to a diverse 
progeny of non-tumorigenic cells) or simply identify a more robust or 
proliferative population of “tumour-initiating” cells selected by engraftment. To 
address this quandary, it will be important to compare the results of side-by-
side fate-mapping experiments and transplantation assays to analyse whether 
the cells endowed with tumorigenic potential after transplantation also exhibit 
the other typical stem-like properties, such as the ability to self-renew, 
asymmetric cell division and differentiation potential55. 
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PDX models of treatment-resistant disease. 
There are primarily two ways in which PDX models can be used to interrogate 
primary or acquired resistance. One strategy is to derive models from 
patients’ samples before initiation of therapy and again at the time of 
treatment resistance. Alternatively, models can be developed from 
pretreatment tumour samples, and resistance can be recapitulated in the PDX 
upon iterative cycles of exposure to the drug, as previously observed in 
genetically engineered mouse (GEM) models56. Using cycles of drug 
exposure in pretreatment PDX models, paired analysis of PDX models of 
cisplatin-sensitive and cisplatin-resistant testicular germ cell cancer (TGCC) 
proposed potential alternatives for the treatment of cisplatin-refractory TGCC, 
including anti-angiogenic therapy57 and blockade of the platelet-derived 
growth factor receptor β (PDGFRβ)–AKT pathway58.  
 
PDX models have also proven useful in identifying mechanisms of resistance 
to targeted therapies in oestrogen receptor (ER)-positive breast cancer. The 
analysis of four hormone-resistant PDX tumours, which were obtained from 
two ER-positive breast cancer PDX models by continuous treatment with 
tamoxifen or by oophorectomy-mediated hormone depletion, revealed that 
hormone resistance was associated with various forms of deregulated ER-
mediated gene transcription33. Taking a similar approach, PDX models of ER-
positive breast cancer have been used to investigate jagged 1 (JAG1)–
NOTCH4 signalling as a means for attenuating sensitivity to hormonal 
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therapy59 and to identify mechanisms of acquired resistance to cyclin-
dependent kinase 4 (CDK4) and CDK6 blockade60. 
 
Patients with advanced cancer who acquire resistance to several lines of 
treatment mostly present with multiple metastatic lesions that are not 
amenable to resection, and may harbour different resistance pathways. 
Generating PDX models that recapitulate such complex scenarios of therapy-
resistant metastatic tumours has become feasible for several tumours (TABLE 
1). For example, analysis of biopsy specimens and corresponding PDXs from 
different drug-resistant metastases in patients with melanoma who had been 
treated with a BRAF inhibitor resulted in the identification of multiple 
resistance mechanisms both within individual lesions and among separate 
samples from the same patient35,38. The resistance mechanisms identified in 
PDXs were also found in the original patient samples35, and clinically resistant 
tumours were also treatment-refractory when grown as PDXs38. These studies 
provide proof of principle for the heterogeneous nature of acquired resistance 
in individual patients with melanoma and further attest to the ability of PDX 
models to predict clinical outcomes. Similar results have been observed in 
lung adenocarcinomas61. 
 
Although PDXs generally retain drug-sensitivity profiles that are similar to 
those of the corresponding patient tumour30,38,62,63, PDX models derived from 
treatment-resistant tumours can become sensitive again upon xenografting, 
owing to the effect of the so-called “drug holiday” in which treatment is 
discontinued after tumour implantation to facilitate engraftment. Some 
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resistance mechanisms are thus reversible in the absence of drug, as shown 
for melanoma64,65 and lung adenocarcinoma66. This suggests that treatment-
resistant PDXs should be exposed to continuous treatment immediately after 
implantation, although this is a cost- and labour-intensive approach. However, 
uninterrupted therapy might also result in the further selection of a 
subpopulation of tumour cells, resulting in a loss of intra-tumour heterogeneity 
and genetic variation in the PDX tumours compared with the original tumours.  
 
In response to the need for more sophisticated models, several groups (for 
example, see REF.67) have developed protocols and networks to generate 
clinical trial-associated xenografts (CTAXs) (TABLE 1). These advanced PDX 
models are currently being derived from image-guided biopsy samples taken 
at different time points during disease progression and following new lines of 
treatment in the context of clinical trials. Such models will be extremely 
valuable in evaluating how the molecular evolution of advanced tumours is 
associated with innate or acquired drug resistance, and will be important for 
studying the tumour heterogeneity and clonal selection that results from drug 
treatment. In principle, CTAXs may also serve as personalized cancer models 
to test drug combinations that aim to overcome acquired resistance, 
generating information that could be transferred back to the donor patient for 
therapeutic decisions (see below). However, this opportunity might be 
hindered by limitations such as the low engraftment success rates for some 
tumour types and the disconnection between the time needed for PDX 
expansion and treatment (which can be long, especially for tumours with 
indolent growth in mice) and the rapidity of disease progression in patients. 
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Finally, PDXs that are established from tumours resistant to conventional 
therapies delivered in the neoadjuvant setting are of special interest (TABLE 
1). In triple-negative breast cancer, the establishment and molecular profiling 
of PDXs from residual cancer cells that persist after neoadjuvant treatment 
(minimal residual disease (MRD)) may lead to the identification of targetable 
molecular alterations in the chemotherapy-resistant component of the tumour, 
which may mirror micro-metastases that are destined to clinically recur68. 
Despite often being limited in size due to prior exposure to cytotoxic therapy, 
triple-negative breast tumours from patients treated in the neoadjuvant setting 
engraft much more efficiently than do treatment-naive tumours (72% and 
34%, respectively) (TABLE 2). Given the high engraftment efficiency and 
rapid growth of PDXs from drug-tolerant MRD tissues, at least in the case of 
breast cancer, these models represent an unprecedented opportunity to 
identify genomic alterations and associated targeted therapies before tumour 
recurrence in patients.  
 
 
Next-generation PDX models 
Humanized PDX models to evaluate cancer immunotherapies. The 
importance of the immune system in tumour progression and treatment 
highlights the need for PDX models to facilitate the preclinical assessment of 
cancer immune therapies69. However, to avoid immune rejection of 
xenotransplants by the host, PDX models are primarily generated by 
transplanting tumour fragments into immunodeficient mice. The absence of 
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many components of the immune system in these mice, and the loss of 
endogenous human immune cells upon propagation of the human tumour 
tissue over multiple passages70,71, limit the utility of such models to explore 
the role of the immune system in tumour progression and to test novel 
immune-based therapies72.  
 
Humanized mice (also known as human haemato-lymphoid chimeric mice or 
human immune system (HIS) models) are immunocompromised mice in 
which selected immune components have been introduced to generate a 
competent human immune system with different degrees of immune 
reconstitution. One methodology for the generation of humanized mice 
involves the transplantation of total peripheral blood from healthy human 
donors or patients (peripheral blood lymphocyte(PBL) models) or, in particular 
applications, the infusion of tumour-infiltrating lymphocytes (TILs) (FIG. 1). 
Although these procedures are known to cause severe graft-versus-host 
disease (GvHD) beginning 2-5 weeks after injection73,74, seriously limiting the 
useful investigative time window of these models and the translational value 
of these studies75, PBL and TIL mice can be used for cost-effective short-term 
testing of novel immune therapeutics and for assessing short-term adverse 
effects.  
 
Alternatively, HIS mice can be generated through the transplantation of CD34-
positive human haematopoietic stem cells (HSCs) or precursor cells isolated 
from umbilical cord blood, bone marrow and peripheral blood, either alone or 
in combination with additional human immune tissues (bone ossicles or 
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human thymic tissue)76 into immunodeficient mice (FIG. 1). Compared with 
PBL- and TIL-derived models, transplantation with HSCs results in a more 
complete haematopoietic reconstitution, as HSCs give rise to various lineages 
of human blood cells throughout the life of the animal. Methods for 
transplantation depend on the source of HSCs, the co-transplantation of 
immune tissues, the mouse strain and the age of the recipient mice75-78. In 
order to avoid the immune reactions caused by human leukocyte antigen 
(HLA) mismatch, the ideal source of HSCs is the same patient from whom the 
PDX has been established. However, isolating HSCs from cancer patients 
may prove daunting: on the one hand, bone marrow biopsies are difficult in 
debilitated individuals; on the other hand, growth factor-stimulated bone 
marrow mobilization for HSC collection from peripheral blood might foster 
tumour progression79 Moreover, even when applicable, the low yield of HSCs 
obtainable from cancer patients severely limits the number of mice than can 
be humanized. An attractive alternative is the in vitro expansion of HSCs80, 
although this procedure could introduce biological perturbations affecting 
stemness and differentiation potential. 
 
Whereas various strains of immunodeficient mice are used to transplant solid 
tumour tissue, not all of these strains are suitable for generating HIS models. 
The survival of human immune cells is highly dependent on the compatibility 
of the “do-not-eat-me” signals (CD47–signal-regulatory protein α (SIRPα)) on 
phagocytes in the host81. The most commonly used mice to generate 
compatible HIS models are those derived from the non-obese-diabetic (NOD)-
severe combined immune deficiency (SCID)-interleukin-2 receptor common -
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chain (IL2-R)-deficient (NSG; also known as NOD.Cg-Prkdcscid 
Il2rgtm1Wjll/SzJ) strain and the NOD/Sci-SCID/IL-2R strain (NOG; also known 
as NOD-Cg-Prkdcscid Il2rgtm1Sug/JicTac). Substantial efforts are thus being 
made to develop novel GEM strains that not only express human-specific do-
not-eat-me signals but also express human-specific cytokines or HLAs. These 
mouse strains differ upon transplantation in durability and quality of 
engraftment of the human immune system78. Some key examples of how 
humanized models are currently evolving to support PDX transplantation 
towards application in the immune-oncology space are presented as online 
supplementary information (see Supplementary information S1 (table)). 
 
Modelling metastatic disease. Subcutaneous transplantation usually fails to 
reproduce the organ-specific tropism of distant metastases that is observed in 
patients. Therefore, models of metastatic disease are typically generated 
through orthotopic procedures. These include the transplantation of fragments 
of the primary tumour into the same location in the mouse, which is usually 
followed by the development of spontaneous metastases, or the direct 
transfer of metastatic lesions into the same organ in the host (TABLE 1). 
Patient-derived orthotopic xenografts (PDOXs; also known as 
orthoxenografts) of primary tumours can reproducibly lead to local invasive 
growth and metastases, often identical to those observed in the patient82-84. 
PDOX models for most cancer indications have typically been developed from 
surgical specimens. More recently, however, they have been successfully 
derived from biopsy samples, despite the limited quantity and quality of tissue 
available85. 
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Advantages of orthotopic models include the ability to investigate tumour-host 
interactions at the relevant site of primary and secondary tumour growth, the 
development of patient-like metastases, the ability to interrogate site-specific 
dependence of therapy, and the potential to conduct clinically relevant 
studies, such as monitoring the effects of adjuvant therapy on occult 
metastases (TABLE 1). Nevertheless, orthotopic models remain relatively 
rare, probably owing to the non-trivial microsurgical procedures that are 
required for organ-specific transplantation. Furthermore, the incorporation of 
clinically relevant imaging modalities and appropriate in vivo imaging probes 
is necessary to visualize tumour orthotopic implants and metastatic 
progression in deep tissues and to ensure timely therapeutic intervention 
when animals develop disease symptoms86. 
 
PDOX models of breast cancer are particularly amenable for modelling 
metastasis. They primarily rely on mammary fat pad injection of primary 
tumour samples, which successfully recapitulate the entire metastatic process 
from the appropriate primary anatomic site8,87. PDOX models of brain 
metastases and primary brain tumours are challenging. To prevent the default 
seeding of intravenously injected tumour cells in the lung and to ensure 
colonization of the central nervous system, intra-cardiac left ventricular 
inoculation of tumour cells is required88. Cells may also be implanted 
intracranially to overcome the blood-brain barrier89. Orthotopic homing and 
the metastatic potential of cancer cells can be boosted by genetic 
modification; for example, colorectal cancer PDX cells engineered to express 
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C-C motif chemokine receptor 9 (CCR9) efficiently localize to the mouse 
colon after tail-vein injection, attracted by the abundance of the CCR9 ligand 
C-C motif chemokine ligand 25 (CCL25) in the intestine, and then 
spontaneously metastasize to the liver90. Genetic manipulation is useful to 
develop models of spontaneous metastasis for mechanistic studies in vivo; 
however, the introduction of exogenous molecules to patient-derived material 
may affect some properties of the original tumour, thus reducing translational 
relevance. 
 
Whether PDOX models more accurately recapitulate clinical response to 
anticancer drugs compared with conventional subcutaneous PDX models 
remains to be established. One report showed that the antitumoural effects of 
a microtubule-stabilizing drug on PDX models of brain metastases from non-
small-cell lung cancer were different in orthotopic versus subcutaneous 
implants85, but results remain anecdotal. It is conceivable that therapies that 
target components of the tumour microenvironment, such as endothelial cells 
and immune cells, would be better evaluated in an orthotopic context. 
Conversely, the therapeutic response of “oncogene-addicted tumours”, which 
intrinsically rely on activating mutations for their growth and survival, is likely 
to be less dependent on anatomical location and more influenced by the 
underlying cancer genetic makeup. Indeed, despite their heterotopic location, 
subcutaneous PDXs from BRAF-mutant melanoma9,91 and HER2 (also known 
as ERBB2)-amplified colorectal cancer6,92,93 mimic the therapeutic response 
observed in patients. Sharing results from different experimental models 
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within the EurOPDX consortium will allow us to shed some light on this critical 
question. 
 
CTC-derived PDX models. As mentioned above, a step forwards for 
minimally invasive tumour sampling is the isolation and characterization of 
CTCs, detected at low concentrations in the peripheral blood of patients with 
different solid tumours40. Although the role of CTCs in metastasis 
development is still uncertain40, their levels ostensibly correlate with patient 
survival and response to therapy94-96. These features mean that CTCs are 
promising tools to monitor cancer burden and drug susceptibility in metastatic 
and late-stage disease, when repetitive biopsies are not indicated. 
Technological advances now allow the isolation of viable CTCs, which 
maintain tumorigenicity when xenografted in immunocompromised mice97-99 
(TABLE 1). 
 
Several reports have demonstrated the feasibility of establishing CTC-derived 
PDX models by directly injecting freshly isolated and enriched CTCs from 
patients with different cancers into immunocompromised mice. Using various 
CTC-capture techniques (such as epithelial cell adhesion molecule (EPCAM) 
or cytokeratin-based selection of cancer cells derived from epithelial tissues or 
microfluidic-based leukocyte depletion100,101), CTC-derived xenografts are 
now practicable for breast cancer97, prostate cancer102, gastric cancer103, 
small-cell lung cancer (SCLC)98 and melanoma91. Moreover, it has also been 
shown that ex vivo cultivated and fully molecularly characterized breast104 and 
colorectal105 CTCs maintain their tumorigenic potential. Notably, both freshly 
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isolated CTCs and CTC-derived PDXs genetically and histologically mirror the 
original tumour and retain analogous drug sensitivities91,97,98,100,102-105. As an 
example, PDXs that are established from chemotherapy-naive circulating 
SCLC cells recapitulate donor patients’ response to both platinum and 
etoposide98. In patients with ER-positive breast cancer, CTCs have also 
proven to be a useful model to study the genetic evolution of the tumour and 
to identify novel drug susceptibilities104.  
 
Although technically challenging, the use of CTC-derived PDX models opens 
new possibilities for translational research. In addition to being a source of 
information regarding disease prognosis106, tumour heterogeneity107,108, 
evolution109 and dissemination110,111, CTC-derived PDXs hold promise for 
precision medicine applications (TABLE 1). For instance, CTCs from women 
with treatment-refractory ER-positive breast tumours have been recently 
analysed to investigate the functional and phenotypic consequences of 
prolonged anti-hormonal therapies, and xenografts from such CTCs have 
been used to design new therapies to overcome resistance112. Similarly, the 
next-generation sequencing of tumours, complemented with genomic analysis 
of CTCs and CTC-derived PDX mouse models, has proven to be a powerful 
platform for developing precision medicine strategies in patients with 
melanoma91. This approach has, in specific cases, facilitated the clinical 
implementation of alternative therapeutic strategies informed by the preclinical 
models91. 
 
 
  22 
PDXs for clinical decision-making 
PDX population xenopatient trials. Across tumours of the same origin, 
genetic lesions that sustain tumorigenesis (and that therefore associate with 
response to targeted drugs) often involve many different oncogenes, each of 
which is mutated at low frequency113. Furthermore, genotype-based prediction 
of drug response is not unequivocal. Despite harbouring the genetic lesion 
known to correlate with drug response, many tumours do not regress due to 
the presence of signals that compensate for target inhibition114. Collectively, 
this information indicates that the genetic selection of tumours for the 
application of targeted therapies requires representative study populations 
and suitable pharmacogenomic platforms. 
 
Provided that they are generated in high numbers and extensively 
characterized at the molecular level, PDXs can act as a powerful resource for 
large-scale genotype-response correlations and therapeutic studies in 
genetically defined tumour subsets. Several recent studies testify to this 
potential; in late-stage colorectal cancer, for example, a systematic 
assessment of response to antibodies targeting epidermal growth factor 
receptor (EGFR) using PDX models (“xenopatients”) derived from hundreds of 
individual tumours was coupled to candidate-gene or whole-exome 
sequencing analyses. Through this effort, several genetic determinants of 
resistance to EGFR blockade were discovered, including amplifications or 
mutations in genes encoding druggable kinases6,7,115,116. Similarly, more 
dynamic features such as expression changes in pro-survival genes and the 
activation of compensatory feedback loops during treatment were identified as 
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mechanisms of tumour adaptation to EGFR family117,118 or MEK119 inhibition in 
colorectal cancer. The flexibility of PDXs also enabled preclinical testing of 
drug combinations in models displaying some of these resistance traits, with a 
permutation capability that was clearly beyond the number of testable 
hypotheses in humans (FIG. 2).  
 
An analogous population-based drug screen has been recently performed in 
more than 1,000 PDX models representing a wide range of solid cancers (the 
‘PDX Encyclopaedia’)9. Some genetic hypotheses and biomarkers of drug 
sensitivity, which emerged from cultured cancer cell lines, were successfully 
validated in this large panel of PDX models (FIG. 2). Notably, experiments in 
PDXs also enabled the identification of therapeutic candidates that in vitro 
model systems failed to capture9. In all these studies, responses obtained in 
mice were highly consistent with responses in patients. For example, the 
distribution of tumour regression, disease stabilization and progression in 
colorectal cancer xenopatients receiving EGFR antibodies was similar to that 
found in the clinic, and treatment-refractory tumour grafts were enriched for 
known genetic predictors of therapeutic resistance in patients6 (TABLE 3); 
moreover, in analogy with clinical studies120, the addition of an EGFR small-
molecule inhibitor to the EGFR antibody increased tumour regression118. 
Similarly, PDXs from BRAF-mutant melanomas underwent substantial 
shrinkage when treated with BRAF inhibitors, a response that was further 
magnified – as in patients – by the addition of a MEK inhibitor9,121. PDX 
platforms have recently been used for the systematic identification of cancer 
vulnerabilities through RNA interference-based genetic screens in tumour 
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grafts, which have revealed new oncogenic drivers in melanoma122 and 
pancreatic tumours123. 
 
PDX population trials may be highly informative, but they are also expensive 
and technically cumbersome, and the trade-off between sufficient sample size 
to ensure adequate coverage of inter-patient heterogeneity and experimental 
feasibility requires careful study design. To reduce the number of animal 
replicates while preserving statistical power, reproducibility studies have been 
conducted to compare response calls made on a single mouse with majority 
responses in reference cohorts composed of many animals. Thus, a strong 
concordance between single-mouse responses and majority responses has 
been found, with a prediction accuracy varying from 75%124 to 95%9. 
Accordingly, ‘one animal per model per treatment’ (1 x 1 x 1) approaches 
have been recently advocated9,125.  
 
Alternative strategies to reduce experimental burden could rely on step-wise 
approaches, whereby large-scale pharmacogenomic screens are performed 
using less laborious formats (such as cancer cell lines) followed by in vivo 
validation in selected, molecularly relevant PDX models. In this regard, it is 
noteworthy that patient-derived material from human tumours, such as 
colorectal, pancreas and prostate cancers126-132, can be grown and nearly 
indefinitely expanded as three-dimensional (3D) organoids. These can be 
easily transplanted to establish PDXs, and vice versa, and are amenable to 
drug screens in a semi-high-throughput manner130. Albeit more difficult to 
establish and propagate, two-dimensional (2D) primary cultures of dissociated 
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cancer cells from both patient samples and PDXs are also being attempted 
with similar rationale and objectives133. In this vein, a platform for drug testing 
in short-term cultured breast cancer cells from PDXs has been recently 
developed and shown to predict in vivo drug response29. 
 
PDX co-clinical ‘Avatar’ trials. The term co-clinical trial refers to 
simultaneous clinical and preclinical trials with anticancer agents in patients 
with a tumour type of a defined genetic makeup and a mouse model with 
similar genetic abnormalities134. The underpinning idea is that comparison of 
responses between the patients and the preclinical model will help to define 
the mechanism of action of a given drug, as well as biomarkers of response. 
Originally implemented with GEM models, the co-clinical trial concept has 
been expanded to include PDX models (“avatars”), which are generated from 
cancer patients enrolled in clinical trials and, in parallel, treated with the same 
drug or drugs that the patient is receiving10 (FIG. 2). In general, these studies 
aim to develop a PDX model from newly diagnosed patients and use it to 
explore therapies that can be administered to the patient at the time of 
disease progression. Ongoing trials cover different tumour settings, including 
sarcomas (NCT02720796)135, head and neck carcinomas (NCT02752932)136, 
ovarian cancer (NCT02312245)137 and pancreatic cancer (NCT02795650)138. 
Although a cogent argument exists for implementing avatar trials, and several 
case reports have provided data to support the concept139-141, the logistical 
difficulties and technical hurdles are likely to limit the broad applicability of this 
approach (see above). 
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PDX models in biomarker development. The validation of mechanisms that 
link specific biomarkers to treatment efficacy will have direct clinical effects, 
allowing patient stratification for tailored treatment protocols. Large-scale PDX 
trial formats, such as the PDX Encyclopaedia9 mentioned above, represent a 
more accurate approach to identify predictive biomarkers compared with the 
use of cell lines (TABLE 1). A transcriptional profiling study on 85 PDX models 
of nine different cancer types treated with nine separate cancer drugs 
identified 1,578 genes, the expression of which correlated with sensitivity to at 
least one drug; 333 of these genes showed significant association with 
sensitivity to two or more drugs, and 32 genes predicted response to six or 
seven drugs142. This type of study provides an initial set of biomarkers that 
require further evaluation in clinical material to determine translatability into a 
clinically useful assay.  
 
Epigenetic biomarkers, such as DNA methylation, can also be assessed in 
PDXs as possible response predictors. A study including 28 glioblastoma 
PDOXs showed that the poly(ADP-ribose) polymerase (PARP) inhibitor 
veliparib significantly enhances the efficacy of temozolomide (TMZ) 
chemotherapy only in models with O-6-methylguanine-DNA methyltransferase 
(MGMT) promoter hyper-methylation143. On the basis of these data, MGMT 
promoter hyper-methylation was included as an eligibility criterion for TMZ 
and veliparib combination treatment in an ongoing] phase II/III glioblastoma 
clinical trial (NCT02152982)144. 
 
Determinants of therapeutic sensitivity can be identified at the protein level 
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using pathway analysis in PDXs: a proteomic survey of 20 PDX models of 
glioblastoma and their parental tumours identified a subset of cases with 
comparable proteomic profiles displaying high levels of expression and 
phosphorylation of EGFR and its downstream signalling proteins145. The 
expression and phosphorylation status of EGFR and downstream targets 
might be used as a predictive biomarker of response to EGFR inhibition in 
preclinical trials and, if successful, included in future clinical trials aiming at 
inhibiting EGFR signalling in patients with glioblastoma. 
 
PDX models are also useful for the preclinical identification of metabolic 
biomarkers using magnetic resonance spectroscopy (MRS). This technique 
has recently been used to demonstrate differences in metabolic 
characteristics between molecular subtypes of breast cancer146,147. Elevated 
phosphocholine levels and low glycerophosphocholine levels have been 
proposed to be metabolic markers of aggressive disease in breast cancer 
based on in vitro studies148. However, MRS on intact tissue from PDX models 
of poor-prognosis basal-like breast cancer displays an inverted metabolic 
profile, with high glycerophosphocholine rather than high phosphocholine 
concentration146,147. These observations suggest that proper tumour 
architecture, as maintained in PDXs, influences choline metabolism. 
Accordingly, a strong correlation between PDX models and clinical material 
was observed in the expression of genes that are involved in key metabolic 
pathways146. MRS technology also holds potential for in vivo non-invasive 
detection of metabolic biomarkers through tailored techniques such as 31P 
MRS or hyperpolarized 13C MRS149,150. Recently, a proof-of-principle study 
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demonstrated the ability of in vivo MRS to distinguish basal-like from luminal-
like breast cancer PDXs non-invasively using 31P MRS imaging151.  
 
For some cancer types, the ability of tumours to successfully engraft in mice 
can be considered per se a surrogate biomarker of risk for disease 
progression. For example, in mammary tumours, the ability to generate stable 
tumour grafts significantly predicted reduced survival8,152, and gene 
expression signatures associated with successful PDX engraftment correlated 
with worse survival outcome when tested in prognostically annotated data 
sets of triple-negative breast cancer153. Similarly, tumour grafts of pancreatic 
ductal adenocarcinoma displayed higher expression of metastasis-associated 
genes compared with samples that failed engraftment, and patient donors of 
successfully engrafted tumours had shorter survival154.  
It is now well established that human tumour stromal cells are replaced by 
mouse counterparts following engraftment155. As a consequence of this 
substitution, species-specific RNA sequencing-based expression profiling of 
PDXs offers a unique opportunity to distinguish mouse stroma-derived 
transcripts from human cancer cell-derived transcripts without the need to 
physically separate the two components before RNA extraction. Such 
analyses led to the identification of stromal-associated transcriptional 
signatures in colorectal cancer associated with poor prognosis and treatment 
resistance156. The negative prognostic significance of tumour stromal 
transcriptional signatures and their value for therapeutic decision-making and 
patient follow-up have also been described in other reports157,158.  
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Challenges and opportunities 
Ideal animal models for preclinical experimentation in oncology should fulfil 
several criteria: reflecting the diversity of cancer patients at the 
epidemiological and molecular levels; retaining, to the highest possible extent, 
the functional, phenotypic and genotypic characteristics of human tumours; 
faithfully predicting response to therapies, and recapitulating mechanisms of 
innate and acquired resistance, and allowing for experimental flexibility.  
 
Although PDXs fulfil several of these criteria and can be further improved to 
meet additional requirements, certain inherent limitations remain difficult to 
address. A major obstacle is the necessity of using immunocompromised 
mice to circumvent xenograft rejection. This requirement hampers the use of 
current PDX models to assess immunotherapeutics. Although emerging 
humanization procedures are now expected to overcome some of the most 
important concerns (see Supplementary information S1 (table)), issues still 
remain with the incorporation of particular immune cell types, immune 
responses and lymphoid structures in these humanized models and with the 
eradication of xenogeneic GvHD. It is expected that the development of novel 
immune-deficient mice will take advantage of emerging technologies based 
on engineered nuclease enzymes for genome editing (such as transcription 
activator-like effector nuclease (TALEN) and CRISPR–Cas9). These 
modifications will include the replacement or introduction of combinations of 
human-specific cytokine receptors and adhesion molecules, as well as more 
comprehensive sets of HLA class I and class II molecules.  
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As mentioned above, serial passaging of tumours leads to substitution of 
human stroma by murine components, and mouse-derived cytokines and 
growth factors in some cases do not crossreact with receptors that are 
expressed by human (cancer) cells159-162. This makes the contribution of the 
tumour microenvironment to drug response difficult to assess in PDXs. 
Moreover, the lack of a species-compatible tumour stroma complicates the 
identification of pharmacodynamic markers of target inactivation for drugs that 
intercept cancer-related microenvironmental processes, such as angiogenesis 
and inflammation. While mouse humanization procedures seek to reconstitute 
the human immune system, the replacement of stromal elements such as 
endothelial cells and fibroblasts with their human counterparts is currently 
daunting, if not unfeasible.  
 
PDX-based efforts for cancer precision medicine also require adequate 
logistics, from proper archival biobanking to continuous propagation of live 
biospecimens, intensive animal experimentation and systematic integration of 
therapeutic results with high-content molecular annotation. The perception of 
this complexity and the awareness that resource sustainability cannot be 
maintained by individual academic laboratories have fuelled initiatives for 
creating and implementing shared large-scale PDX platforms, including the 
European EurOPDX resource, the US National Cancer Institute (NCI) 
repository of patient-derived models, the Public Repository of Xenografts 
(PRoXe), the Children's Oncology Group (COG) cell culture and xenograft 
repository, and the Pediatric Preclinical Testing Consortium (PPTC) (BOX 1).  
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When dealing with such large multi-institutional platforms, standardized 
methodological procedures should be carried out to ensure reproducibility and 
to streamline readouts so that they are interpretable across different 
laboratories (BOX 1). Further, therapeutic outcomes should be univocally 
deciphered and stringently interpreted. Retardation of tumour growth during 
therapy typically results in tumours that are smaller than controls at end point, 
but larger than they were before starting treatment; while this may well 
suggest that the therapy is biologically active (because it affects cancer cell 
proliferation), it is not an indication that the therapy is clinically effective; 
indeed, this kind of response would be clinically defined as ‘disease 
progression’ or, at best, ‘disease stabilization’. In the EurOPDX experience, 
even manifest effects of tumour growth inhibition – as observed, for example, 
after blockade of MEK in PDXs of KRAS-mutant colorectal cancer125 – did not 
translate into clinical benefit when analogous therapies were applied to 
patients163. By contrast, overt regression in PDXs predicted positive results in 
the clinic: the finding that an antibody and small molecule combination against 
HER2 induced massive regressions in HER2-amplified colorectal tumour 
grafts6,117 has been recently translated into a successful clinical trial, with the 
vast majority of patients achieving tumour shrinkage when treated with the 
same regimen93. It has also become increasingly clear that the use of 
quantitative metrics to classify response (equivalent to clinical Response 
Evaluation Criteria in Solid Tumours (RECIST)) should be implemented to 
more precisely assess therapeutic effects in PDX trials. Modified RECIST 
criteria for mouse xenograft applications have recently been described9. ‘Best 
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response’ is defined as the minimum value of percentage tumour volume 
change, compared with tumour volume at baseline, for treatment durations 
equal to or longer than 10 days, and ‘best average response’ is the minimum 
value of the mean percentage of tumour volume change, as measured at 
each evaluation time point along treatment, compared with baseline9. Such 
definitions, coupled with specific tumour volume cut-offs, have been applied to 
categorize complete response, partial response, stable disease and 
progressive disease in tumour-bearing mice. These modified RECIST criteria 
capture response kinetics, robustness and durability, and thus improve the 
ability of preclinical studies to accurately predict patient outcome. 
 
Extended and detailed molecular annotation is a prerequisite for precision 
oncology paradigms. However, the accumulation of multiple layers of genomic 
information requires the development of computational systems with common 
or interoperable standards for normalization, correction and retrieval of 
complex data sets. The issue of big data collection, harmonization and 
storage is particularly critical when working with large PDX collections, in 
which one original tumour from a single patient gives rise, upon serial 
passages, to many descendants that expand at an exponential rate (BOX 2). 
In EurOPDX, efforts are ongoing to aggregate cancer genomic profiles 
obtained through different technologies in different laboratories and to 
implement a user-friendly, open-source portal that showcases the molecular 
characteristics of the participating collections (BOX 1). Importantly, besides 
the detection of individual variants with clinically actionable potential, multi-
dimensional molecular information from existing PDX models can be 
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subjected to systems-based bioinformatics analysis to extract algorithms that 
identify key biological parameters164. Preliminary evidence suggests that such 
algorithms can be subsequently used to identify one or more ‘biofacsimile’ or 
‘proxy’ PDX models for individual patients, and PDX-associated information 
may be leveraged to instruct treatment options and/or to derive predictive 
indicators in the clinic164 (FIG. 2).  
 
All these considerations underscore the opportunities offered by PDX models 
to illuminate new angles of translational cancer research, but they also put 
forward the challenges that are intrinsic to this approach, and the need for 
finding new ways to maximize PDX potential. Industry-led PDX ventures rely 
on common and extensively tested operating procedures, backed by 
considerable funding, which ensures scalable, homogeneous and 
reproducible experimental schemes; however, pharmaceutical initiatives are 
typically bound to preclinical testing of proprietary compounds and may face 
obstacles in publishing results, especially when data relate to sensitive 
commercial or patenting issues. Conversely, due to their multi-institutional 
nature, scholarly consortia usually suffer from heterogeneous characterization 
of their PDX collections, a flaw that is hardly corrected by the relatively limited 
resources provided by government or charity grants; however, PDX academic 
efforts enjoy flexibility in drug testing and unfettered scientific reporting 
(including reporting of negative results, which avoids the duplication of effort 
and reduces costs). As EurOPDX members working in academia, we share 
with our colleagues of PRoXe the concern that “academic centers are ill 
suited to bear the burden of housing, expanding, archiving, characterizing, 
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and disseminating PDXs to investigators (academic and industrial) across the 
world”(REF. 165). Meanwhile, we believe that joining forces, incorporating 
models, coordinating methodologies, and improving the public shareability 
and visibility of molecular data in an academic-oriented rather than industry-
scale format are viable objectives that will foster not only a stronger 
collaborative spirit in cancer medicine, but also a change of mind-set within 
institutional authorities and industrial stakeholders. EurOPDX has started as a 
crowd-funded initiative of scientists with common goals, complementary skills 
and similar needs, and is now growing in a more structured fashion thanks to 
enterprise-wide development plans. Ultimately, we envision a virtuous circle in 
which new knowledge from bottom-up efforts like ours and others will inform 
clinical decision making, which in turn will orient public and private financial 
interests to secure further sustainability of PDX-based activities. Successful 
examples in other contexts of biomedical research, such as 
TRANSAUTOPHAGY (see Further information; a European consortium for 
multidisciplinary research and translation of knowledge on autophagy) and 
GENiE (see Further information; a network of scientists using Caenorhabditis 
elegans as a model organism), bode well to achieve this ambition. 
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BOX 1 - The EurOPDX Consortium and other related initiatives 
EurOPDX (see Further information; established in 2013) is a collaborative 
network of 16 European academic institutions with expertise in basic, 
preclinical, translational and clinical oncology. Participating laboratories are 
affiliated with comprehensive cancer centres within which preclinical 
experimentation is closely associated with clinical activities. This allows for the 
efficient sharing of patient specimens – together with fully annotated clinical 
information – and facilitates the collection of tumours with unique 
characteristics (for example, rare types, exceptional responders and therapy-
refractory cases). Currently sustained by membership fees organized by a 
consortium agreement, EurOPDX aims to obtain competitive infrastructural 
funding to further implement collaborative research projects and formalize 
external access procedures to models. The consortium agreement also sets 
forth general rules for confidentiality and intellectual property issues to 
regulate activities among EurOPDX members (co-ownership of results) and 
between EurOPDX and potential partners, including other patient-derived 
xenograft (PDX) consortia and industry. 
 
 
MAIN OBJECTIVES: 
 To create a uniquely extensive collection of characterized PDX models. 
The collection consists of more than 1,500 subcutaneous and 
orthotopic models from over 30 different pathologies (see TABLE 2). 
The models and their molecular annotation are currently being made 
publicly available through the cBioPortal, and are accessible for 
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collaboration upon signature of a material transfer agreement. 
Systematic derivation of primary cultures and organoids for in vitro 
studies is planned. 
 To provide a platform for population-scale studies to discover low-
prevalence genetic alterations with clinically actionable potential; to 
explore mechanisms of therapeutic resistance in molecularly defined 
tumour subtypes; and to develop predictive biomarkers for 
personalized cancer treatment. 
 To harmonize working practices. This entails several aspects: first, 
standardization of biobanking procedures, including systematic 
assessment of genetic identity by single nucleotide polymorphism 
(SNP) DNA fingerprinting. Second, the implementation of common 
rules for PDX expansion and archiving; discussions are ongoing to limit 
PDX propagation to a maximum of 5 passages, but exceptions will be 
considered for tumour types known to deteriorate after freezing-
thawing steps and for models characterized by very indolent growth, for 
which expansions up to 5 passages would take exceedingly long. 
Third, optimization of inter-laboratory reproducibility through proof-of-
concept studies by which models from the same source are tested 
independently. And finally, the definition of a set of minimal information 
to be linked to each PDX. 
 
 
OTHER MAJOR PDX INITIATIVES: 
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 US National Cancer Institute (NCI) repository of patient-derived models 
(see Further information). 
 US Pediatric Preclinical Testing Consortium (PPTC; see Further 
information), a US National Cancer Institute (NCI)-centralized and NCI-
funded collection for in vivo testing of paediatric anticancer drug 
candidates. 
 Children's Oncology Group (COG) cell culture and xenograft repository 
(see Further information), a COG-based resource that provides 
validated cell lines and PDXs from paediatric cancers. 
 Public Repository of Xenografts (PRoXe; see Further information), an 
open-source repository of leukemia and lymphoma PDXs165. Many of 
the models are being licensed to the Jackson Laboratories for industry-
scale purposes, including distribution on a fee-for-service basis 
 Novartis Institutes for Biomedical Research PDX Encyclopedia (NIBR 
PDXE), an industry-led initiative that includes approximately 1,000 
models9. Clinical, pathological and PDX-level data from this collection 
are currently being incorporated into PRoXe165. 
 
 
BOX 2 - Data management and integration 
By combining the flexibility of preclinical analysis with the instructive value of 
population-based studies, patient-derived xenografts (PDXs) offer 
unprecedented opportunities for drawing statistically robust correlations 
between genetic or functional traits and sensitivity to anticancer drugs. 
However, the advantages of high-throughput studies with PDX-based 
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approaches may become major hurdles when dealing with large-scale data 
management, analysis and utilization. The deployment of PDX models for 
translational studies often requires their stratification into existing predictive or 
prognostic molecular classes and subgroups as derived on tumours from 
patients. The portability of the stratification criteria from human to mice, and 
vice versa, is not trivial, owing to multiple sources of biological and genomic 
variation, which may be introduced in the process of engrafting and 
propagating patient tumour material into murine hosts. 
 
DATA MANAGEMENT ISSUES: 
 Data complexity and dynamics. The representation of cancer data in 
classical oncogenomic portals is normally static: the results obtained by 
analysing such public resources are not fed back to refine, update or 
complement the original information. The possibility to incrementally 
stratify and integrate multiple layers of information generated from the 
same original sample by diverse laboratories at different times 
represents one of the key added values of PDX-based approaches. 
This implies the need for further dimensions of complexity to 
interrogate an almost infinite number of variables and to implement 
decision-making algorithms in case of data inconsistency across 
experiments166. 
 Data normalization and annotations. The joint utilization of human and 
PDX data requires the standardization of sample metadata such as 
clinical and molecular ontologies. Through this effort, data derived from 
different experiments, technologies and platforms can be normalized 
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against common categories and used to interrogate samples with 
integrative queries exploring heterogeneous data domains.  
DATA ANALYSIS ISSUES: 
 Population selection bias. Owing to the different engraftment efficacies 
inherent to each tumour sample, the population of xenografts might not 
recapitulate the full distribution of tumour phenotypic or molecular 
variables observed in patients. Any prior-dependent statistical models 
should be adapted to the new distribution of subclasses within the PDX 
population. This implies the necessity to identify the missing or 
underrepresented subgroups through analytical investigation of 
multidimensional parameters (genomics, transcriptomics, 
histopathology, and so on). 
 Loss of human immune and stromal cells. Athough both stromal and 
immune components are replaced over time by murine analogues, the 
haematopoietic elements show important differences in their spatial 
distribution167 or may be missing overall156,168. This affects the signal 
received from molecular profiling, and could require application of 
specific algorithms for signal correction to avoid or reduce artefacts and 
biases156,169. 
 
 
Legend for figures: 
 
Figure 1: Strategies to generate humanized PDXs. Sources of immune 
cells include tumour-infiltrating lymphocytes (TILs), peripheral blood 
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mononuclear cells (PBMCs) and CD34-positive haematopoietic stem cells 
(HSCs); HSCs may be purified from mobilized adult peripheral blood, bone 
marrow or umbilical cord blood. Engrafted TILs or PBMCs generate mainly 
circulating human leukocyte antigen (HLA)-restricted T cells and natural killer 
(NK) cells (top row). This system is characterized by a vigorous graft-versus-
host reaction that narrows the experimental window to approximately 2-5 
weeks. Despite this limitation, the system is useful for certain analyses, such 
as monitoring the recruitment of T lymphocytes to tumours by therapeutic 
antibodies170. Fully humanized systems (bottom four rows) use severely 
immunodeficient mouse strains such as NOG (NOD-Cg-Prkdcscid 
Il2rgtm1Sug/JicTac)171, NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjll/SzJ)172 and BRG 
(C.Cg-Rag1tm1Mom IL2rgtm1Wjl/SzJ)173,174. Mice with a NOD (non-obese 
diabetic) background have functionally deficient NK cells. SCID (severe 
combined immunodeficiency) is a loss-of-function mutation that affects DNA-
dependent protein kinase (DNA-PK), a DNA repair enzyme involved in V(D)J 
recombination during T cell and B cell development. As a consequence, SCID 
mice have reduced levels of T cells and B cells. Inactivation of the interleukin-
2 (IL-2) receptor γ-chain leads to impaired T cell and B cell development and 
prevents the generation of NK cells. Recombination-activating gene 1 (RAG1) 
is necessary for V(D)J recombination; thus, RAG1 inactivating mutations 
affect T cell and B cell development. All these different strains show subtle 
differences to support engraftment of functional human immune cells173. 
Injection of human CD34-positive HSCs into these mice leads to the 
generation of major histocompatibility complex (MHC)-restricted T cells and B 
cells, as well as to limited amounts of monocytes, macrophages, neutrophils 
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and dendritic cells. In addition, these mouse strains have been improved by 
genetic modifications for the production of a variety of human cytokines that 
stimulate the differentiation of additional haematopoietic lineages. For 
example, strains such as NOG-GM3 (which expresses human IL-3 and 
granulocyte-macrophage colony-stimulating factor (GM-CSF; also known as 
CSF2)175, NSG-SGM3 (which expresses human IL-3, GM-CSF and SCF (also 
known as KIT ligand))176 and MISTRG (which expresses human IL-3, GM-
CSF, macrophage CSF (M-CSF, also known as CSF1), signal regulatory 
protein-α (SIRPα) and thrombopoietin (THPO))177 produce increased numbers 
of human myeloid and mast cells, regulatory T cells and NK cells (see 
Supplementary information S1 (table)). PDXs, patient-derived xenografts. 
 
Figure 2: PDX preclinical study designs. a. Large collections of patient-
derived xenograft (PDX) models (‘xenopatients’) now allow population-based 
studies to be carried out, which better mimic the inter-tumour heterogeneity 
that is seen in patients and are more predictive of clinical efficacy than 
conventional xenografts of immortalized cancer cell lines. PDX molecular 
characterization and correlation with therapeutic response also facilitates 
biomarker discovery, as well as identification of primary (and acquired) 
resistance mechanisms. These studies can lead to new hypotheses and 
support the initiation of new clinical trials. b. For some cancer types for which 
avatar models can be developed, co-clinical avatar studies allow for 
simultaneous drug testing in mice and patients for real-time adaptive 
therapeutic decisions. c. In the “biofacsimile” or “proxy” study format, 
integrative systems-based bioinformatics analysis can be used to pinpoint the 
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best-matched PDX for a given patient from a collection of molecularly profiled 
models. PDX-associated information is then leveraged to instruct clinical 
treatment options and/or derive prognostic indicators. NGS, next generation 
sequencing. 
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Table 1: Modelling cancer phenotypes with PDX models 
 
PDX model  Open clinical question Advantages Challenges 
Primary tumour specimens 
implanted s.c. 
 Interrogation of primary or 
acquired resistance 
mechanisms  
 Discovery of prognostic and 
predictive biomarkers 
 Drug response 
 Identification of targetable 
molecular alterations 
 Characterization of intra-
tumour clonal evolution 
 Intact primary tumour tissue 
that maintains tumour 
architecture  
 Captures clonal diversity 
 Easy to measure tumour 
responses 
 Intravital tumour imaging 
 Lack of proper anatomical 
niche 
 Not all grades of tumour 
engraft s.c. Generally, higher 
grade, more aggressive 
tumours engraft more easily. 
Primary tumour specimens 
implanted orthotopically (PDOX) 
 Mechanisms of metastasis 
 Study site-specific 
dependence of therapy 
 Monitoring the effects of 
adjuvant therapy on occult 
metastasis 
 Stromal contribution to 
response 
 Intact primary tumour tissue 
that maintains primary 
tumour architecture 
 Local growth of primary 
tumour in proper anatomical 
context 
 Spontaneous distant 
metastases from primary 
tumour 
 Presence of primary and 
metastatic tumour niche 
 Recapitulates the entire 
metastatic process from the 
appropriate anatomical site 
 Ability to mimic clinical 
scenarios, for example, 
surgical removal of primary 
tumour or adjuvant therapy  
 Access to imaging 
technologies to visualize 
tumour in longitudinal studies 
 Microsurgical skills 
 Large collections and high-
throughput screens difficult 
to implement 
Metastatic tumour specimens 
implanted s.c. 
 Interrogation of primary or 
acquired resistance 
mechanisms  
 Discovery of prognostic and 
 Intact metastatic tumour 
tissue that maintains tumour 
architecture  
 Lack of tumour metastatic 
niche 
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predictive biomarkers 
 Drug response 
 Identification of targetable 
molecular alterations 
 Characterization of intra-
tumour clonal evolution 
Metastatic tumour specimens 
implanted orthotopically at the 
metastatic site 
 Mechanisms of metastasis 
 Drug resistance 
 Genetic and cellular 
mechanisms of tumour 
growth 
 Drug response in the setting 
of metastatic disease 
 Stromal contribution to 
response 
 Intact metastatic tumour 
tissue that maintains tumour 
architecture 
 
 Access to imaging 
technologies to visualize 
tumour in longitudinal studies 
 Microsurgical skills 
 Large collections and high-
throughput screens difficult 
to implement 
PDX models of MRD   Drug resistance 
 Discovery of prognostic and 
predictive biomarkers 
 Biological and 
pharmacological studies 
 Identification of targetable 
molecular alterations 
 Studies can help us to 
understand the molecular 
bases of and optimize 
therapies for MRD 
 Higher tumour take rate 
when compared with 
untreated cancers 
 Enables study of clonal 
evolution and cancer stem 
cell behaviour 
 PDXs are never therapy 
naive. 
Clinical trial-associated xenografts 
(CTAXs)  
 Discovery of prognostic and 
predictive biomarkers  
 Drug resistance 
 Drug response 
 Identification of targetable 
molecular alterations 
 Mechanisms of metastasis 
 Possibility to establish 
xenografts at different clinical 
stages during patient tumour 
progression  
 Permits the parallel testing of 
novel drug combinations 
 Limited quantity and quality 
of tissue 
 Limited number of 
successfully generated PDXs 
 A PDX derived from a single 
biopsy sample may not 
represent the patient’s 
tumour. 
CTC-derived PDX models  Molecular tumour 
heterogeneity 
 Minimally invasive sampling 
 Ability to monitor cancer 
 Low concentration in 
peripheral blood of patients 
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 Discovery of prognostic and 
predictive biomarkers 
 Study of the genetic 
evolution of the tumour 
 Identification of targetable 
molecular alterations  
burden and drug 
susceptibility in metastatic 
and late-stage settings 
 Recapitulates donor patient's 
response to treatment 
 Facilitates investigation of 
the biology of otherwise 
inaccessible tumour 
specimens 
with different solid tumours 
 Access to technologies to 
isolate all CTCs (both 
epithelial and mesenchymal) 
 Technically challenging 
Humanized PDX models  Investigation of immune 
therapeutics 
 Recapitulates human 
immune system in mice 
 Requires lengthy mouse 
humanization procedures 
 Hurdles to achieve complete 
human immune system 
reconstitution 
 See Supplementary 
information S1 (table) for 
further details 
 
CTC, circulating tumour cell; MRD, minimal residual disease; PDX, patient-derived xenograft; PDOX, patient-derived orthotopic xenograft; s.c., 
subcutaneously 
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Table 2: Facts and figures about the EurOPDX collection* 
 
   
 
 
Average engraftment 
rate: treatment naive 
and adjuvant samples 
(%) 
Engraftment rates: 
neoadjuvant 
samples (if 
relevant) (%) 
Tumour type 
or Organ 
Subtype 
Primary 
tumour or 
metastasis 
Total 
number of 
established 
models 
Subcutane
ous 
Orthotopic 
Subcu
taneo
us 
Orthotopic 
CRC 
All subtypes 
included   Primary 291 52-75 80 NA NA 
     
Liver 
metastasis 444 73-91 90 84 NA 
Pancreas 
(PDAC) 
All subtypes 
included 
 
Primary 211 54-71 70 NA NA 
 
  
 
Liver 
metastasis 24 60-100 90 NA NA 
Breast ER+ (incl. 
ER+HER2+) 
 Primary 24 4-7 7 20 NA 
   Metastasis 20 25-49 33-47 NA NA 
  
TNBC 
 Primary 78 30-34 60-86 72 86 
   Metastasis 26 60 50-66 NA NA 
  
HER2+ only 
 Primary 16 26 NA 13 NA 
   Metastasis 5 NA 33 NA NA 
Skin 
melanoma 
All subtypes 
included 
 
Primary 
8 67-90 29 NA NA 
  
Metastasis 
(cutaneous, 
liver, lung) 
161 
72-90 83-85 NA NA 
Ovary 
All subtypes 
included   Primary 123 40-85‡ 68 62‡ NA 
     Metastasis 19 47-85‡ 80 NA NA 
Gastric 
All subtypes 
included 
 
Primary 
87 41-50 70 34 NA 
Endometrial All subtypes  Primary 67 43-55 74 NA NA 
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included 
     Metastasis 10 10-60§ 95 NA NA 
Lung NSCLC 
 
Primary and 
metastasis  59 
50-70 
(primary) 52 NA NA 
 
SCLC 
 
Primary and 
metastasis 
12 50 75 
Not 
applica
ble 
Not 
applicable 
HNSCC 
All subtypes 
included   Primary 50 45 65 NA NA 
     Metastasis 13 83   NA NA 
Glioblastoma 
All subtypes 
included 
 
Primary 52 
Not 
applicable 95-100 
Not 
applica
ble NA 
Uveal 
melanoma 
All subtypes 
included    Primary 12 32 NA 
Not 
applica
ble 
Not 
applicable 
     
Liver 
metastasis 14 65 NA 
Not 
applica
ble 
Not 
applicable 
Testicular 
All subtypes 
included 
 
Primary and 
metastasis 
(lymph 
node, lung 
and brain) 
18 NA 35 NA NA 
Uterine 
Sarcoma High grade   Primary 3 75 NA 
Not 
applica
ble 
Not 
applicable 
     Metastasis 9 100 NA 
Not 
applica
ble 
Not 
applicable 
Renal 
All subtypes 
included 
 
Primary 8 30 NA NA NA 
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CRC, colorectal cancer; ER, oestrogen receptor; HNSCC; head and neck squamous cell carcinoma; NA, not available; NSCLC, non-small-cell lung cancer; 
PDAC, pancreatic ductal adenocarcinoma; SCLC, small-cell lung cancer; TNBC, triple-negative breast cancer. *The data presented represent the range of 
implantation rates obtained across EurOPDX partner laboratories as of October 2016. ‡Highest take rates obtained with the high-grade serous ovarian 
cancer subtype. §Take rates of 10–15% for abdominal, pelvic lymph node and peritoneal metastases, 60% for vaginal metastases. 
 
 
Table 3: Comparative quantitative data of response rates in PDXs versus human patients 
 
Tumour type Clinical question Comparative response rates 
CRC* Response to EGFR antibody 
monotherapy in genetically unselected 
CRC PDXs6, or unselected 
chemorefractory patients with CRC178 
PDXs: 
 PR: 5 of 47 (10.6%) 
 SD: 14 of 47 (29.8%) 
 PD: 28 of 47 (59.6%) 
Patients: 
 PR: 12 of 111 (10.8%) 
 SD: 24 of 111 (21.6%) 
 PD: 59 of 111 (53.2%) 
 Not evaluated: 16 of 111 
(14.4%) 
CRC*  PDXs118: Response to EGFR antibody 
monotherapy in KRAS, NRAS and BRAF 
wild-type models 
 Patients179: Response to EGFR 
antibody plus chemotherapy in 
chemorefractory patients with KRAS, 
NRAS and BRAF wild-type CRC 
PDXs: 
 PR: 31 of 125 (24.8%) 
 SD: 60 of 125 (48%) 
 PD: 34 of 125 (27.2%) 
Patients: 
 PR: 15 of 56 (26.8%) 
 SD: 29 of 56 (51.8%) 
 PD: 12 of 56 (21.4%) 
NSCLC Co-clinical trial, PDX versus donor 
patient66: response to EGFR small-
molecule inhibitors in four representative 
cases out of six established PDXs 
1 PR (both patient and PDX) 
1 SD (both patient and PDX) 
2 PD (both patient and PDX) 
Breast 
cancer 
Co-clinical trial, PDX versus donor 
patient63: response to several therapies 
 Doxorubicin: 
4 PD (both patient and PDX) 
 
 Docetaxel: 
1 PR (both patient and PDX) 
6 PD (both patient and PDX) 
 
 Anti-HER2 combination therapy (trastuzumab 
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and lapatinib): 1 PR (both patient and PDX) 
 
CRC, colorectal cancer; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; PD: progressive disease; PDX, patient-derived 
xenograft; PR, partial response; SD, stable disease. *Data represent separate PDX and patient population studies. 
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ToC summary 
This Opinion article discusses progress and challenges in using patient-
derived tumour xenograft (PDX) models in cancer precision medicine. It is 
primarily co-authored by members of the EurOPDX Consortium and as such 
highlights the merits of shared PDX resources. 
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Supplementary Information S1 | Examples of improvements in humanised mouse models for PDX studies 
 
Pending issues Details Circumvention or solutions Models (Supplier or Developer) 
Graft versus Host 
Disease (GvHD) 
Engraftment with mature human T cells 
leads to xenogeneic GvHD due to 
mismatch between murine MHC and 
human HLA in engrafted cells or tissues. 
 Use of genetically modified 
mouse strains that develop reduced 
or no GvHD  
  GvHD reported to depend on 
HLA haplotype of HSC donor1 
 Immune-deficient strains lacking B2m (NSG-B2m), 
MHC-I (NSG-(KbDb)null or MHC-II (NSG-(H2-Ab)null 
(Jackson Laboratory2,3) 
 B6RG-Cd47: C57BL/6 mice lacking Rag2 and Il2rg, 
and deficient for CD474. Absence of GvHD due to 
improper “education” and functionality of mouse 
myeloid cells. However, functionality of human myeloid 
cells still to be validated. 
HLA restriction of T 
cells and 
compatibility with 
tumours 
Absence of human HLA molecules on 
thymic epithelial cells generates human 
T cells unable to recognize de novo 
antigens (eg. Tumor specific antigens) in 
a HLA-restricted manner in HSC 
transplanted mice5. 
 Transplantation of human 
thymus tissue (BLT/ Bone Liver 
Thymus mice)6 
 Use of human HLA class I 
and/or class II transgenic immune 
deficient mice7-11 
 E.g. NOG-Dr4 mice (Taconic); NSG-Dr1, NSG-Dr4 
or NSG-HLA-A2 mice (Jackson Laboratory). 
Species-specific 
cytokines and 
factors 
Some human cytokines or factors are 
species specific, preventing generation 
or maintenance of specific human 
immune cell types. 
 New mouse strains expressing 
human cytokines or receptors to 
obtain a more complete human 
immune system12 
 Onset of anaemia described as 
a limitation for many of the current 
models with improved myeloid 
reconstitution. Efforts being made to 
avoid anaemia for example by 
introducing human CD47. 
Immune deficient mouse strains transgenic for human 
cytokines to promote myeloid and NK lineage 
commitment include: 
 NOG-GM3: NOG mice expressing human GM-CSF 
and IL-3 (CIEA, Japan)13; 
 NSG- SGM3: NSG mice expressing human IL-3, 
GM-CSF and SCF (Jackson Laboratory14); 
 MISTRG: BALB/c x 129S4 Rag2;Il2rg double ko 
mice expressing human M-CSF, GM-CSF, IL-3, 
THPO and a human SIRPA allele15; 
 NOG-hIL6: NOG mice expressing human IL6 
(Taconic), featuring increased human monocytes and 
macrophages (in particular M2 type)  
 NSG-W41: NSG mice with mutated mouse Kit. 
Reduced mouse haematopoiesis results in higher 
human reconstitution levels without the need to 
 2 
precondition mice. Display improved human myeloid 
reconstitution as compared to NSG mice16. 
 NOGh-IL2: NOG mice expressing human IL2, 
featuring higher numbers of human NK cells 
(Taconic17) 
Remaining mouse 
innate immunity 
Despite multiple gene modifications to 
eliminate mouse immune cells, 
commonly used NSG and NOD mice 
still have mouse myeloid cells 
(macrophages, dendritic cells and 
granulocytes) which can play a role in 
tumour biology18. 
 Models with reduced mouse 
innate immune cells. These include 
strains transgenic for human 
myeloid specific cytokines 
mentioned earlier. 
 Immune-deficient mice further 
modified to functionally incapacitate 
remaining innate cells. 
 NSG-Tlr4-/-: facilitates monitoring of human TLR4 
responses only (mentioned in19) 
 BRGF: Rag2-deficient, Il2rg-deficient BALB/c 
(BRG) mice lacking mouse Flt3, resulting in loss of 
mouse dendritic cells, increased numbers of human 
dendritic cells, NK and T cells20 
 B6RG-Cd47 mice (as above) 
Impaired humoral 
immune 
responses, low Ig 
levels and impaired 
Ig 
class switching 
B cells in humanised NSG or NOG mice 
do not undergo sufficient maturation to 
become memory and antibody-
producing cells21. 
Development of new mouse strains: 
 e.g. human HLA class II 
transgenic mice, with improved 
humoral responses due to 
increased CD4-mediated help22; 
 Mice strains transgenic for human 
cytokines23; 
  Improved lymphoid organ 
development resulting in increased 
B cell development and Ig class 
switching (see below). 
 SRG-IL6: Rag2;Il2rg double ko mice with a 
human SIRPA allele and expressing human IL6 show 
increase in development of CD45+ cells, in particular 
B cells and class switched B cells (discussed in24)  
 Human HLA class II transgenic NSG or NOG 
mice7,9 
Impaired lymph 
node development, 
poorly developed 
germinal centres 
• Defects in cytokine signalling in 
immune-deficient strains results in poorly 
developed secondary lymphoid tissues 
(NSG, NOG and BRG are all Il2rg-
deficient25). This includes poor germinal 
centre formation, ineffective class 
switching of B cells and antigen 
presentation to naïve T cells, impeding 
robust adaptive immune responses upon 
humanisation26. 
 Mouse models with restored 
secondary lymphoid tissue 
development. 
 Discussed in24 
 NOG-pRorgt-IL2Rg: transgenic NOG mice in 
which IL2R expression is driven by the promoter of 
Rort, an isoform of Rorc whose expression is 
restricted to the thymus. This leads to specific IL2R 
expression in lymphoid tissue inducer cells resulting 
in normal lymph node development and improved B 
cell maturation and Ig class switching. 
Impaired Immunodeficient strains based on NOD  Use immune-deficient mice  NSG-C5a: NSG-C5a mice have the intact Hc gene, 
 3 
complement 
system  
background lack hemolytic complement 
due to a mutation in the C5 complement 
gene, preventing the formation of the 
C5b-9 membrane attack complex18. 
These mice lack complement dependent 
cytotoxicity in e.g. antibody dependent 
therapies. 
strains that do not have the NOD 
background such as SRG mice. 
 Genetically modified NOD 
based mice that have a functional 
C5 gene. 
restoring the complement system27. 
 
 
 
B2m, beta2-microglobulin; DR, Antigen D-related; Flt3, Fms-like tyrosine kinase 3; GM-CSF, granulocyte-macrophage colony stimulating factor; GvHD, Graft 
versus Host Disease; Hc, hemolytic complement; HSC, haematopoietic stem cell; Ig, immunoglobulin; Il2rg, interleukin 2 receptor common gamma chain; IL2, 
interleukin 2; IL3, interleukin 3; IL6, interleukin 6; ko, knockout; M-CSF, macrophage colony-stimulating factor; NK, natural killer; Rag2, recombination 
activating gene 2; SCF, stem cell factor; SIRPA, signal-regulatory protein ; TLR4, toll-like receptor 4; THPO, thrombopoietin. 
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